Search

Your search keyword '"Janet Woodcock"' showing total 4 results
Start Over Author "Janet Woodcock" Publisher american association for the advancement of science (aaas)
4 results on '"Janet Woodcock"'

1. The NIH-led research response to COVID-19

Author

Francis Collins, Stacey Adam, Christine Colvis, Elizabeth Desrosiers, Ruxandra Draghia-Akli, Anthony Fauci, Maria Freire, Gary Gibbons, Matthew Hall, Eric Hughes, Kathrin Jansen, Michael Kurilla, H. Clifford Lane, Douglas Lowy, Peter Marks, Joseph Menetski, William Pao, Eliseo Pérez-Stable, Lisa Purcell, Sarah Read, Joni Rutter, Michael Santos, Tara Schwetz, Jeffrey Shuren, Timothy Stenzel, Paul Stoffels, Lawrence Tabak, Karen Tountas, Bruce Tromberg, David Wholley, Janet Woodcock, and John Young

Subjects
Multidisciplinary
Abstract

Investment, collaboration, and coordination have been key

Published
2023
Full Text
View/download PDF

2. Medication development in opioid addiction: Meaningful clinical end points

Author

Sharon Hertz, Nora D. Volkow, Eric M. Wargo, Janet Woodcock, Douglas C. Throckmorton, Wilson M. Compton, and Phil Skolnick

Subjects
medicine.medical_specialty, United States Food and Drug Administration, business.industry, media_common.quotation_subject, Outcome measures, General Medicine, Abstinence, Opioid-Related Disorders, United States, 03 medical and health sciences, 0302 clinical medicine, Drug Development, Drug development, New medications, Humans, Medicine, 030212 general & internal medicine, business, Intensive care medicine, Drug Approval, Opioid addiction, 030217 neurology & neurosurgery, media_common
Abstract

The FDA’s “abstinence” outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.

Published
2018
Full Text
View/download PDF

3. Immune-mediated pathology in Duchenne muscular dystrophy

Author

V. Ashutosh Rao, Montserrat Puig, Kanneboyina Nagaraju, Amy S. Rosenberg, S. Armando Villalta, Lalage M. Wakefield, Eric P. Hoffman, and Janet Woodcock

Subjects
Duchenne/ Becker Muscular Dystrophy, musculoskeletal diseases, congenital, hereditary, and neonatal diseases and abnormalities, Intellectual and Developmental Disabilities (IDD), Duchenne muscular dystrophy, Clinical Trials and Supportive Activities, Inflammation, Biology, Medical and Health Sciences, Article, Dystrophin, Pathogenesis, Rare Diseases, Immune system, Clinical Research, medicine, Humans, Innate, 2.1 Biological and endogenous factors, Muscular Dystrophy, Aetiology, Muscular dystrophy, Pediatric, Autophagy, Immunity, Neurosciences, General Medicine, Biological Sciences, Duchenne, medicine.disease, Fibrosis, Immunity, Innate, TGF-beta Superfamily Proteins, Brain Disorders, Muscular Dystrophy, Duchenne, Musculoskeletal, Immunology, biology.protein, Cytokines, Signal transduction, medicine.symptom, Signal Transduction
Abstract

Immunological and inflammatory processes downstream of dystrophin deficiency as well as metabolic abnormalities, defective autophagy, and loss of regenerative capacity all contribute to muscle pathology in Duchenne muscular dystrophy (DMD). These downstream cascades offer potential avenues for pharmacological intervention. Modulating the inflammatory response and inducing immunological tolerance to de novo dystrophin expression will be critical to the success of dystrophin-replacement therapies. This Review focuses on the role of the inflammatory response in DMD pathogenesis and opportunities for clinical intervention.

Published
2015
Full Text
View/download PDF

4. FDA Regulations for Drug Development

Author

Janet Woodcock and Rachel E. Behrman

Subjects
medicine.medical_specialty, Multidisciplinary, business.industry, Cancer therapy, Pharmacology, Food and drug administration, Clinical research, Drug development, medicine, medicine.symptom, Intensive care medicine, business, health care economics and organizations, Confusion
Abstract

The Editorial “Cancer Therapy Reform” by Genentech Chairman A. D. Levinson (9 April, p. [137][1]) highlights possible confusion about U.S. Food and Drug Administration (FDA) regulation of developing therapies. Contrary to Levinson's claims, there is not now, nor has there ever been, a regulation

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results